在患有毛囊前肺高血压的患者中与睡眠相关的障碍
Hsin-Yu Chao1, Brendon J Yee2, Chih-Hsin Hsu3
1Department of Nursing, College of Medicine, National Cheng Kung University, Tainan City, Taiwan.
Sleep medicine reviews
|July 20, 2024
概括
前毛囊性肺高血压 (PcPH) 与睡眠障碍,如睡眠呼吸障碍和不安腿综合征有关. 解决这些睡眠问题可能会改善PCPH患者的生活质量和结果.
科学领域:
- 肺部医学 肺部医学
- 睡眠医学 睡眠医学
- 心脏病学 心脏病学
背景情况:
- 前毛囊性肺高血压 (PcPH) 越来越多地被认为与各种睡眠相关疾病有关.
- 这些睡眠障碍可能会显著影响已经被PcPH症状所负担的患者的生活质量.
研究的目的:
- 审查PcPH患者睡眠障碍的范围.
- 探索PcPH和睡眠障碍之间的病理生理联系.
- 讨论潜在的治疗策略来管理PcPH的睡眠问题.
主要方法:
- 这篇叙事综述综合了目前关于PcPH睡眠障碍的证据.
- 它检查了PcPH与睡眠呼吸障碍,缺氧和不安腿综合征等疾病之间的联系.
- 讨论了病理生理机制和治疗方面的考虑.
主要成果:
- 患有PcPH的患者表现出更高的睡眠质量受损,睡眠呼吸障碍,睡眠相关缺氧和不安腿综合征的患病率.
- 与睡眠相关的缺氧与较差的右心室功能和增加的死亡风险相关.
- 在PcPH中铁的调节失调可能会导致不安腿综合征/睡眠的周期性四肢运动.
结论:
- 睡眠障碍在PcPH中很常见,并会加剧患者的病情.
- 对于PcPH睡眠障碍的氧气和正气道压力等疗法,需要进一步研究.
- 肺高血压和睡眠专家之间的加强合作对于最佳的患者管理至关重要.
相关概念视频
01:30Pulmonary Hypertension: Classification and Pathogenesis
164
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
164
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
193
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
193
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
143
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
143
01:17Other Pulmonary Disorders
813
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
813
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
155
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
155
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
150
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
150